Long-term safety follow-up of people treated with cilta-cel for multiple myeloma
Follows adults with multiple myeloma previously treated with cilta-cel to study late side effects.
Plain-language title generated from the registry record
Registry title: A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Key facts
- Where
- Tel Aviv, IsraelSee the site
- Phase
- Phase 4
Where in Israel
- Tel-Aviv Sourasky Medical CenterTel Aviv, IsraelTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Janssen Research & Development, LLC
- Trial code
- NCT05201781EU 2023-505530-10-00
- Record updated
- 3 November 2026
- Original description
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.Read full original descriptionShow less
Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Inclusion: Participants who have received at least one dose of cilta-cel in a Company-sponsored clinical study; Participants who have provided informed consent for this study.